A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

PHASE3CompletedINTERVENTIONAL
Enrollment

509

Participants

Timeline

Start Date

March 2, 2020

Primary Completion Date

November 9, 2021

Study Completion Date

September 28, 2022

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Bimekizumab

Subjects will receive bimekizumab at pre-specified time-points.

OTHER

Placebo

Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

Trial Locations (91)

19103

Hs0004 50150, Philadelphia

27104

Hs0004 50179, Winston-Salem

27710

Hs0004 50211, Durham

29425

Hs0004 50084, Johns Island

29615

Hs0004 50236, Greenville

30328

Hs0004 50193, Sandy Springs

31419

Hs0004 50223, Savannah

32073

Hs0004 50152, Orange Park

33028

Hs0004 50184, Pembroke Pines

33125

Hs0004 50199, Miami

38219

Hs0004 50144, Orlando

43230

Hs0004 50145, Columbus

45324

Hs0004 50202, Fairborn

46168

Hs0004 50234, Plainfield

48346

Hs0004 50178, Clarkston

60077

Hs0004 50164, Skokie

63110

Hs0004 50105, St Louis

78660

Hs0004 50148, Pflugerville

87106

Hs0004 50237, Albuquerque

89052

Hs0004 50197, Henderson

91320

Hs0004 50196, Thousand Oaks

92708

Hs0004 50162, Fountain Valley

03801

Hs0004 50159, Portsmouth

07044

Hs0004 50200, Verona

Unknown

Hs0004 30018, Parkville

Hs0004 30014, St Leonards

Hs0004 30009, Westmead

Hs0004 40313, Pleven

Hs0004 40284, Sofia

Hs0004 40311, Sofia

Hs0004 40314, Sofia

Hs0004 40315, Sofia

Hs0004 40353, Stara Zagora

Hs0004 50172, Cobourg

Hs0004 50135, Edmonton

Hs0004 50174, London

Hs0004 50189, St. John's

Hs0004 50134, Waterloo

Hs0004 50136, Winnipeg

Hs0004 40063, Prague

Hs0004 40194, Prague

Hs0004 40245, Antony

Hs0004 40321, Auxerre

Hs0004 40129, Bordeaux

Hs0004 40320, La Rochelle

Hs0004 40247, Lyon

Hs0004 40130, Marseille

Hs0004 40404, Reims

Hs0004 40403, Saint-Etienne

Hs0004 40286, Toulouse

Hs0004 40289, Berlin

Hs0004 40326, Berlin

Hs0004 40322, Dessau

Hs0004 40356, Dresden

Hs0004 40287, Frankfurt am Main

Hs0004 40142, Hamburg

Hs0004 40328, Hanover

Hs0004 40250, Lübeck

Hs0004 40254, Debrecen

Hs0004 40344, Dublin

Hs0004 20090, Afula

Hs0004 20196, Bunkyō City

Hs0004 20144, Fukuoka

Hs0004 20043, Itabashi-ku

Hs0004 20195, Kagoshima

Hs0004 20170, Kurume

Hs0004 20190, Kyoto

Hs0004 20033, Nagoya

Hs0004 20152, Nakagami-gun

Hs0004 20178, Nishinomiya

Hs0004 20153, Obihiro

Hs0004 20037, Osaka

Hs0004 20154, Sapporo

Hs0004 20171, Sendai

Hs0004 40347, Lodz

Hs0004 40293, Rzeszów

Hs0004 40335, Warsaw

Hs0004 40095, Wroclaw

Hs0004 40333, Wroclaw

Hs0004 40334, Wroclaw

Hs0004 40159, Barcelona

Hs0004 40267, Barcelona

Hs0004 40298, Granada

Hs0004 40268, Madrid

Hs0004 40297, Manises

Hs0004 40101, Sabadell

Hs0004 40300, Cardiff

Hs0004 40339, Leeds

Hs0004 40113, London

Hs0004 40240, Newcastle upon Tyne

Hs0004 40338, Northampton

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04242498 - A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter